Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer
- PMID: 23063071
- DOI: 10.1016/j.cllc.2012.05.009
Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer
Abstract
We present the treatment rationale and study design of the MetLung phase III study. This study will investigate onartuzumab (MetMAb) in combination with erlotinib compared with erlotinib alone, as second- or third-line treatment, in patients with advanced non-small-cell lung cancer (NSCLC) who are Met-positive by immunohistochemistry. Approximately 490 patients (245 per treatment arm) will receive erlotinib (150 mg oral daily) plus onartuzumab or placebo (15 mg/kg intravenous every 3 weeks) until disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death. The efficacy objectives of this study are to compare overall survival (OS) (primary endpoint), progression-free survival, and response rates between the 2 treatment arms. In addition, safety, quality of life, pharmacokinetics, and translational research will be investigated across treatment arms. If the primary objective (OS) is achieved, this study will provide robust results toward an alternative treatment option for patients with Met-positive second- or third-line NSCLC.
Copyright © 2012. Published by Elsevier Inc.
Similar articles
-
Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.Clin Lung Cancer. 2012 Sep;13(5):391-5. doi: 10.1016/j.cllc.2012.01.003. Epub 2012 Mar 21. Clin Lung Cancer. 2012. PMID: 22440336 Clinical Trial.
-
Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.J Clin Oncol. 2017 Feb;35(4):412-420. doi: 10.1200/JCO.2016.69.2160. Epub 2016 Dec 12. J Clin Oncol. 2017. PMID: 27937096 Clinical Trial.
-
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.J Clin Oncol. 2005 Sep 1;23(25):5892-9. doi: 10.1200/JCO.2005.02.840. Epub 2005 Jul 25. J Clin Oncol. 2005. PMID: 16043829 Clinical Trial.
-
Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.Clin Ther. 2005 Oct;27(10):1513-34. doi: 10.1016/j.clinthera.2005.10.014. Clin Ther. 2005. PMID: 16330289 Review.
-
Efficacy of erlotinib in patients with advanced non-small cell lung cancer: a pooled analysis of randomized trials.Anticancer Drugs. 2011 Oct;22(9):842-52. doi: 10.1097/CAD.0b013e328349c303. Anticancer Drugs. 2011. PMID: 21808188 Review.
Cited by
-
MET canonical transcript expression is a predictive biomarker for chemo-sensitivity to MET-inhibitors in hepatocellular carcinoma cell lines.J Cancer Res Clin Oncol. 2021 Jan;147(1):167-175. doi: 10.1007/s00432-020-03395-4. Epub 2020 Sep 26. J Cancer Res Clin Oncol. 2021. PMID: 32980960 Free PMC article.
-
MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis.Onco Targets Ther. 2020 Mar 25;13:2491-2510. doi: 10.2147/OTT.S231257. eCollection 2020. Onco Targets Ther. 2020. PMID: 32273721 Free PMC article. Review.
-
Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance.Appl Immunohistochem Mol Morphol. 2020 Oct;28(9):669-677. doi: 10.1097/PAI.0000000000000810. Appl Immunohistochem Mol Morphol. 2020. PMID: 31876606 Free PMC article.
-
Comparison of in situ and extraction-based methods for the detection of MET amplifications in solid tumors.Comput Struct Biotechnol J. 2019 Sep 11;17:1339-1347. doi: 10.1016/j.csbj.2019.09.003. eCollection 2019. Comput Struct Biotechnol J. 2019. PMID: 31762957 Free PMC article.
-
Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.BMC Cancer. 2018 Nov 26;18(1):1171. doi: 10.1186/s12885-018-5078-y. BMC Cancer. 2018. PMID: 30477470 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous